Taking a closer look at the European Medicines Agency’s Public Assessment Report of the VIEW 1 and VIEW 2 trials comparing efficacy and safety of aflibercept (EYLEA) versus ranibizumab. Voice over: Professor Paul Mitchell, Sydney, Australia. Sponsor: Bayer HealthCare Pharmaceuticals Inc.

Click to Play

This is a White Board illustration of the key comparisons shown in the European Medicines Agency’s Public Assessment Report. In less than 6 minutes Professor Paul Mitchell provides the voice over to this rapid assessment and interpretation of the key elements that have been discussed widely since its publication in 2012. Production and distribution of this video has been paid for by Bayer Healthcare Pharmaceuticals Inc, New Jersey, USA.

G.S.M.STH.12.2013.0227

Please note, this video is not available to persons residing in the U.K.